Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit-Harm Assessments

被引:11
作者
Aschmann, Helene E. [1 ]
Boyd, Cynthia M. [2 ]
Robbins, Craig W. [3 ,4 ,5 ,6 ,7 ]
Chan, Wiley, V [8 ]
Mularski, Richard A. [9 ,10 ,11 ]
Bennett, Wendy L. [12 ]
Sheehan, Orla C. [2 ]
Wilson, Renee F. [13 ]
Bayliss, Elizabeth A. [14 ,15 ]
Leff, Bruce [2 ]
Armacost, Karen [2 ]
Glover, Carol [2 ]
Maslow, Katie [2 ,16 ]
Mintz, Suzanne [2 ,17 ]
Puhan, Milo A. [1 ]
机构
[1] Univ Zurich, Epidemiol Biostat & Prevent Inst, Hirschengraben 84, CH-8001 Zurich, Switzerland
[2] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD USA
[3] Kaiser Permanente Care Management Inst, Ctr Clin Informat Serv, Oakland, CA USA
[4] Kaiser Permanente Natl Guideline Program, Oakland, CA USA
[5] Colorado Permanente Med Grp, Denver, CO USA
[6] Board Trustees, Guidelines Int Network, Denver, CO USA
[7] Clin Educ MOC Portfolio, Permanente Federat, Oakland, CA USA
[8] Kaiser Permanente Northwest Natl Guideline Progra, Portland, OR USA
[9] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA
[10] Northwest Permanente, Dept Pulm & Crit Care Med, Portland, OR USA
[11] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[12] Johns Hopkins Univ, Div Gen Internal Med, Sch Med, Baltimore, MD USA
[13] Johns Hopkins Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[14] Kaiser Permanente, Inst Res Hlth, Denver, CO USA
[15] Univ Colorado, Sch Med, Aurora, CO USA
[16] Gerontol Soc Amer, Washington, DC USA
[17] Family Caregiver Advocacy, Kensington, MD USA
关键词
benefit-harm assessment; benefit-harm balance; evidence selection; guideline development; patient involvement; stakeholder engagement; stratification; PREFERENCES; RISK; METHODOLOGIES;
D O I
10.1016/j.jval.2019.11.007
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: In a previous project aimed at informing patient-centered care for people with multiple chronic conditions, we performed highly stratified quantitative benefit-harm assessments for 2 top priority questions. In this current work, our goal was to describe the process and approaches we developed and to qualitatively glean important elements from it that address patient-centered care. Methods: We engaged patients, caregivers, clinicians, and guideline developers as stakeholder representatives throughout the process of the quantitative benefit-harm assessment and investigated whether the benefit-harm balance differed based on patient preferences and characteristics (stratification). We refined strategies to select the most applicable, valid, and precise evidence. Results: Two processes were important when assessing the balance of benefits and harms of interventions: (1) engaging stakeholders and (2) stratification by patient preferences and characteristics. Engaging patients and caregivers through focus groups, preference surveys, and as co-investigators provided value in prioritizing research questions, identifying relevant clinical outcomes, and clarifying the relative importance of these outcomes. Our strategies to select evidence for stratified benefit-harm assessments considered consistency across outcomes and subgroups. By quantitatively estimating the range in the benefit-harm balance resulting from true variation in preferences, we clarified whether the benefit-harm balance is preference sensitive. Conclusions: Our approaches for engaging patients and caregivers at all phases of the stratified quantitative benefit-harm assessments were feasible and revealed how sensitive the benefit-harm balance is to patient characteristics and individual preferences. Accordingly, this sensitivity can suggest to guideline developers when to tailor recommendations for specific patient subgroups or when to explicitly leave decision making to individual patients and their providers.
引用
收藏
页码:616 / 624
页数:9
相关论文
共 37 条
  • [1] Defining certainty of net benefit: a GRADE concept paper
    Alper, Brian S.
    Oettgen, Peter
    Kunnamo, Ilkka
    Iorio, Alfonso
    Ansari, Mohammed Toseef
    Murad, M. Hassan
    Meerpohl, Joerg J.
    Qaseem, Amir
    Hultcrantz, Monica
    Schunemann, Holger J.
    Guyatt, Gordon
    [J]. BMJ OPEN, 2019, 9 (06):
  • [2] [Anonymous], 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 510
  • [3] Armstrong DM, 2016, CAMB PHILOS CLASS, P3
  • [4] Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
    Aschmann, Helene E.
    Boyd, Cynthia M.
    Robbins, Craig W.
    Mularski, Richard A.
    Chan, Wiley V.
    Sheehan, Orla C.
    Wilson, Renee F.
    Bennett, Wendy L.
    Bayliss, Elizabeth A.
    Yu, Tsung
    Leff, Bruce
    Armacost, Karen
    Glover, Carol
    Maslow, Katie
    Mintz, Suzanne
    Puhan, Milo A.
    [J]. BMJ OPEN, 2019, 9 (08):
  • [5] The democratic interface: technology, political organization, and diverging patterns of electoral representation
    Bennett, W. Lance
    Segerberg, Alexandra
    Knuepfer, Curd B.
    [J]. INFORMATION COMMUNICATION & SOCIETY, 2018, 21 (11) : 1655 - 1680
  • [6] A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions
    Bennett, Wendy L.
    Aschmann, Helene E.
    Puhan, Milo A.
    Robbins, Craig W.
    Bayliss, Elizabeth A.
    Wilson, Renee
    Mularski, Richard A.
    Chan, Wiley V.
    Leff, Bruce
    Sheehan, Orla
    Glover, Carol
    Maslow, Katie
    Armacost, Karen
    Mintz, Suzanne
    Boyd, Cynthia M.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2019, 113 : 92 - 100
  • [7] Using Best-Worst Scaling to Investigate Preferences in Health Care
    Cheung, Kei Long
    Wijnen, Ben F. M.
    Hollin, Ilene L.
    Janssen, Ellen M.
    Bridges, John F.
    Evers, Silvia M. A. A.
    Hiligsmann, Mickael
    [J]. PHARMACOECONOMICS, 2016, 34 (12) : 1195 - 1209
  • [8] A New Initiative on Precision Medicine
    Collins, Francis S.
    Varmus, Harold
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (09) : 793 - 795
  • [9] Epidemiology of Peripheral Artery Disease
    Criqui, Michael H.
    Aboyans, Victor
    [J]. CIRCULATION RESEARCH, 2015, 116 (09) : 1509 - 1526
  • [10] Evidence selection for a prescription drug's benefit-harm assessment: challenges and recommendations
    Fain, Kevin M.
    Yu, Tsung
    Li, Tianjing
    Boyd, Cynthia M.
    Singh, Sonal
    Puhan, Milo A.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2016, 74 : 151 - 157